Guggenheim Names Top Stock Pick in Biotech Sector

Guggenheim Securities has identified ABIVAX SOCIÉTÉ ANONYME as its top investment in the biotechnology sector, following the company's recent first-half 2026 earnings release and business updates. The investment firm rates the stock with a Buy rating and sets a price target of $175. ABIVAX concluded the first half of 2026 with €1.2 billion in pro-forma cash, providing a solid cash runway through the fourth quarter of 2029 based on current operating assumptions.

The company's interactions with regulators have been largely positive, focusing on aligning the submission of obefazimod, its lead candidate, without discussing safety or efficacy. ABIVAX does not currently hold a breakthrough designation or aim to purchase a priority review voucher. The company expects to choose a combination candidate by the end of 2026, with clinical program initiation anticipated by late 2027 or early 2028.

Preclinical studies are underway for obefazimod combinations with α4β7, IL-23, PDE4, and AhR agents. Management favors prioritizing oral α4β7 due to its robust safety profile, although the final selection will depend on data. ABIVAX plans to have a prominent presence at UEGW in Barcelona, Spain, with multiple oral presentations of subgroup analyses from the 44-week maintenance readout, as well as longer-term safety and efficacy results from ongoing Phase IIb studies.

The company projects that obefazimod could secure around 20% market share in the U.S. ulcerative colitis market, which is expected to reach $15 billion by 2032. Guggenheim's model estimates combined UC and Crohn's global peak sales of approximately $5 billion for obefazimod.